賽生藥業(06600.HK)獲納入深港通下港股通股票名單
格隆匯9月6日丨賽生藥業(06600.HK)宣佈,根據深圳證券交易所於2021年9月6日刊發的《關於深港通下的港股通股票名單調整的公吿》,公司為獲納入深港通的合資格股份,自2021年9月6日起生效。
公司相信,公司股份獲納入深港通交易機制,顯示出市場對公司投資價值及增長前景的認同。公司預期,是次納入將有助進一步擴大本公司的股東基礎,提高公司股份的交易流通性,以及支持公司的長期創新驅動和可持續增長。
公司是一家擁有產品開發和商業化集成平台的生物製藥公司。公司在戰略上專注於中國一些最大且發展迅速的存在重大未滿足醫療需求的治療領域,主要為腫瘤及重症感染。憑藉集成平台,公司建立了一個均衡的上市產品組合,包括具有強大現金創造能力的已上市產品以及創新在研藥物,如RRx-001及PEN-866等管線產品具有成為首創或同類最優產品的潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.